We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 619

OIG’s First Audit of Open Payments Program: Compliance Rate High, but Data Needs Improvement
  • Hall Render Killian Heath & Lyman PC
  • USA
  • September 7 2018

Recently, the Department of Health and Human Services Office of Inspector General (“OIG”) released findings of an audit of the Centers for Medicare


CMS Allows Medicare Part D Indication-Based Formulary Design
  • Holland & Knight LLP
  • USA
  • August 30 2018

The Centers for Medicare and Medicaid Services (CMS) has just announced a significant shift in Medicare Part D formulary design to allow Part D


Washington Healthcare Update - Aug 20, 2018
  • McGuireWoods LLP
  • USA
  • August 20 2018

Reps. Phil Roe (R-TN) and Ami Bera (D-CA) are asking colleagues to join them on a letter requesting that CMS Administrator Seema Verma inform Medicare


US pharma companies under increasing legislative pressure, key EU SPC decision and much more in July’s life sciences IP round-up
  • IAM
  • USA
  • August 9 2018

In this month’s round-up of patent news from the life sciences, we report on the latest blow to the St Regis Mohawks’ attempt shield their Restasis


Capitol Hill Healthcare Update
  • Baker & Hostetler LLP
  • USA
  • July 23 2018

This week’s “Capitol Hill Healthcare Update” includes the latest on a series of healthcare bills scheduled for House votes, including one to repeal


DOJ Announces Revised Opioid Anti-Diversion Policy
  • FisherBroyles LLP
  • USA
  • July 16 2018

Last week, the Department of Justice (DOJ) announced that it had finalized new rules to prevent the diversion of prescription opioids in a move


House Opioid Measure Frenzy Continues
  • Quarles & Brady LLP
  • USA
  • July 16 2018

Over a period of two weeks in June, the House passed several bills aimed at combating the ongoing opioid epidemic. Our summary of the earlier measures


Washington Healthcare Update - Jul 16, 2018
  • McGuireWoods LLP
  • USA
  • July 16 2018

In a two-day markup, the House Ways and Means Committee cleared a number of measures related to health savings accounts and a measure that would


U.S. House legislation highlights escalating government-wide focus on opioid abuse
  • Hogan Lovells
  • USA
  • July 6 2018

On June 22 the U.S. House of Representatives passed sweeping legislation that represents "the biggest effort Congress has ever undertaken" to address


Requirements, Benefits, and Possible Consequences of Listing Patents in FDA’s Orange Book
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • July 3 2018

The Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) amended patent law and drug law to facilitate